Revolutionizing Cancer Treatment.
Turning Tumors Into Allies
Reprogramming cancer cells into immune cells directly within the patient to combat solid tumors and redefine cancer care.
What We Do
Turning Tumors into Allies
At Reprogram Biosciences, we are pioneering a groundbreaking immunotherapy approach that leverages gene reprogramming to transform cancer cells into immune-like cell types.
Our vision is to empower the body’s own defenses to fight cancer effectively and affordably.
How It Works
Transformative Science Real-World Impact
Reprogramming Technology
Using a novel therapeutic gene cocktail, we transform cancer cells into immune-like cells, effectively turning the tumor against itself.
Targeted Delivery
Our cutting-edge lipid nanoparticle system ensures precision delivery of the therapeutic gene to solid tumors.
Unmatched Efficacy
This approach has shown prolonged survival in preclinical models and promises to lower healthcare costs by eliminating external procedures.
Why Choose Us
How Reprogram Biosciences Stands Out
Who We Are
Meet The Team
Rustam Esanov
Co-founder, CEO
Dr. Rustam Esanov is a biotech leader with deep expertise in cell reprogramming and genomics, dedicated to developing breakthrough cancer therapeutics. He has led therapeutic development across academia and industry, with experience at Scripps Research, Nuredis, Revance, and Nitrase Tx. As Associate Director at GSK, Rustam drove initiatives at the intersection of genomics and drug discovery. Now, as CEO of Reprogram Biosciences, he is leading the company’s mission to revolutionize solid tumor treatment through in vivo reprogramming, transforming cutting-edge science into life-saving therapies.
Eziz Kuliyev
Co-founder, COO
Dr. Eziz Kuliyev is a biochemist with expertise in protein structure-function relationships, mRNA vaccine development, and immunotherapeutic delivery. He earned his Ph.D. in Biochemistry from Michigan State University and honed his skills in mRNA delivery at UC San Diego. A silver medalist at the International Chemistry Olympiad, Eziz combines scientific excellence with a passion for developing transformative solutions in oncology. At Reprogram Biosciences, Eziz is responsible for company operations and applies his expertise to spearhead the intratumoral delivery of our therapeutic cocktail to solid tumors.
Angela Yang
Head of Research
Dr. Angela Yang is a scientific leader and innovator with extensive expertise in cancer biology, functional genomics and single-cell technologies. She previously led teams at GSK and Genentech, where she advanced pioneering tools, including CRISPR-based and single-cell multiomic approaches, to decode gene regulatory networks and cell fate decisions in complex disease models. A co-inventor on multiple patents in stem cell differentiation, she brings a proven track record of scientific innovation and translational insight. As Head of Research, Angela is leading the design of novel genomic and cell differentiation strategies to deliver effective and durable cell therapies for cancer.
Annageldi Tayyrov
Head of AI Platform
Dr. Annageldi Tayyrov is a bioinformatics and data platform leader specializing in AI-driven biological data processing and cloud-native software development. He earned his Ph.D. from ETH Zurich, where he worked at the intersection of computational biology and genomics. Before joining Reprogram Biosciences, he built scalable data platforms at ImmunAI to accelerate AI-driven drug discovery. With over ten years of experience in bioinformatics and computational science across academia and industry, he now leads Reprogram’s AI platform, driving the computational engine that enables precise cell reprogramming and powers the company’s next generation of therapeutics.
Contact Us
We'd love to hear from you
Contacts:
Email: info@reprogrambio.com
1030 Brittan Ave, San Carlos, CA, 94070
Get in touch
Have a question or feedback? Fill out the form below, and we'll get back to you as soon as possible.